STOCK TITAN

Kamada (KMDA) VP General Counsel discloses option grants on Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

KAMADA LTD executive Livneh Nir, the company’s VP and General Counsel, filed an initial Form 3 reporting holdings of stock options on ordinary shares. The filing lists several option grants with exercise prices of 5.6200 and 7.5500, expiring between 2029-10-23 and 2035-10-22. The options, covering blocks such as 9,485, 10,000 and 15,000 underlying ordinary shares, are held directly and are exercisable using a net-exercise method.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Livneh Nir

(Last) (First) (Middle)
120 TAMAR ST.

(Street)
NEGBA L3 7954000

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/13/2026
3. Issuer Name and Ticker or Trading Symbol
KAMADA LTD [ KMDA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP, General Counsel
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase Ordinary Shares(1) 04/23/2024 10/23/2029 Ordinary Shares 9,485 $5.62 D
Options to purchase Ordinary Shares(1) 04/23/2025 10/23/2029 Ordinary Shares 10,000 $5.62 D
Options to purchase Ordinary Shares(1) 04/23/2026 10/23/2029 Ordinary Shares 10,000 $5.62 D
Options to purchase Ordinary Shares(1) 10/22/2026 10/22/2035 Ordinary Shares 15,000 $7.55 D
Options to purchase Ordinary Shares(1) 04/23/2027 10/23/2029 Ordinary Shares 10,000 $5.62 D
Options to purchase Ordinary Shares(1) 10/22/2027 10/22/2035 Ordinary Shares 15,000 $7.55 D
Options to purchase Ordinary Shares(1) 10/22/2028 10/22/2035 Ordinary Shares 15,000 $7.55 D
Options to purchase Ordinary Shares(1) 10/22/2029 10/22/2035 Ordinary Shares 15,000 $7.55 D
Explanation of Responses:
1. These options to purchase ordinary shares are exercisable using a net-exercise method.
/s/ Nir Livneh 03/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Kamada (KMDA) executive Livneh Nir report on this Form 3?

Livneh Nir reports existing option holdings on Kamada’s ordinary shares. The Form 3 lists several grants of options to purchase ordinary shares at specified exercise prices and expirations, establishing his initial reported equity-based position as VP and General Counsel.

What types of securities are reported by Livneh Nir in the Kamada (KMDA) Form 3?

The filing reports options to purchase Kamada ordinary shares. Each line reflects options with defined exercise prices and expiration dates, referencing underlying ordinary shares rather than currently owned common stock, and all are reported as directly held positions.

What are the exercise prices and expirations of Livneh Nir’s Kamada (KMDA) options?

The options carry exercise prices of 5.6200 and 7.5500. Expiration dates run through 2029-10-23 for earlier grants and 2035-10-22 for later grants, providing a long-dated equity incentive profile for the Kamada executive.

How many underlying Kamada (KMDA) shares are covered by Livneh Nir’s options?

The options cover multiple blocks of underlying ordinary shares. Individual grants include 9,485-share, 10,000-share and 15,000-share tranches, each tied to specific exercise prices and expiration dates, illustrating the size and structure of his equity incentives.

How are Livneh Nir’s Kamada (KMDA) options exercisable according to the Form 3?

The options are exercisable using a net-exercise method. A footnote states that these options to purchase ordinary shares may be exercised via net exercise, meaning shares are delivered after offsetting the exercise cost and applicable obligations in shares rather than cash.

Does the Kamada (KMDA) Form 3 show new buying or selling by Livneh Nir?

The Form 3 functions as an initial ownership statement, not a trade report. It lists existing option grants and their terms, with transaction codes and directions shown as unknown, and no buy or sell transactions indicated in the summarized data.
Kamada Ltd

NASDAQ:KMDA

View KMDA Stock Overview

KMDA Rankings

KMDA Latest News

KMDA Latest SEC Filings

KMDA Stock Data

501.25M
31.45M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Rehovot